Scholarlink

<p>The current research aims to synthesize and characterize zwitterion-functionalized mesoporous silica nanoparticles (MSNs) as carriers of Lappaol F for breast cancer therapy to achieve better drug delivery results and improved therapeutic outcomes. Synthesis of zwitterion-functionalized MSNs had surfactant-templating processes and Box-Behnken design optimized the method. MSNs were considered as ideal carriers because of their high surface area, tunable pore size, and overcoming of Lappaol F’s poor aqueous solubility and poor bioavailability issues. The researchers compared physical characteristics, stability data and drug release patterns having cytotoxic effect on MCF-7 breast cancer cells after formulation of drug delivery system. Crucial parameters were investigated in the process of optimization of CTAB concentration (0.25–1.0&#xa0;g) with TEOS volume (5–10&#xa0;mL) and temperature (65–90&#xa0;°C) as main parameters. The optimized design produced nanoparticles measuring 87.5 ± 5.4&#xa0;nm in size with a surface area of 932.4 ± 13.8 m<sup>2</sup>/g and zeta potential level of − 17.7 ± 1.1&#xa0;mV. The drug release pattern exhibited Higuchi-type kinetics (<i>R</i><sup>2</sup> = 0.9988) which displayed dual release phases leading to 83–93% drug release during 12&#xa0;h. The formulated product demonstrated stability under accelerated testing at 40 ± 2&#xa0;°C with 75 ± 5% RH during a 6-month period while critical properties remained stable. The cytotoxicity analysis showed significant concentration-dependent toxicity effects over a 48-h period leading to 29.85% cell viability at a 75&#xa0;µg/mL concentration level while exhibiting similar toxicity as standard 5-FU treatment. The LCYS-LFF-MSNs demonstrated optimized physicochemical properties, remarkable stability, and promising in vitro anticancer activity, representing a novel zwitterionic nanocarrier system for Lappaol F delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and Fabrication of Zwitterionic Functionalised Mesoporous Silica Nanoparticles of Lappaol F for Breast Cancer

  • 期刊论文

  • 发表日期：

    2025年6月25日

查看全文
  • Someshwar D. Mankar,
  • Ankush M. Tambade,
  • Suhas S. Siddheshwar,
  • Payal S. Gawali

摘要

The current research aims to synthesize and characterize zwitterion-functionalized mesoporous silica nanoparticles (MSNs) as carriers of Lappaol F for breast cancer therapy to achieve better drug delivery results and improved therapeutic outcomes. Synthesis of zwitterion-functionalized MSNs had surfactant-templating processes and Box-Behnken design optimized the method. MSNs were considered as ideal carriers because of their high surface area, tunable pore size, and overcoming of Lappaol F’s poor aqueous solubility and poor bioavailability issues. The researchers compared physical characteristics, stability data and drug release patterns having cytotoxic effect on MCF-7 breast cancer cells after formulation of drug delivery system. Crucial parameters were investigated in the process of optimization of CTAB concentration (0.25–1.0 g) with TEOS volume (5–10 mL) and temperature (65–90 °C) as main parameters. The optimized design produced nanoparticles measuring 87.5 ± 5.4 nm in size with a surface area of 932.4 ± 13.8 m2/g and zeta potential level of − 17.7 ± 1.1 mV. The drug release pattern exhibited Higuchi-type kinetics (R2 = 0.9988) which displayed dual release phases leading to 83–93% drug release during 12 h. The formulated product demonstrated stability under accelerated testing at 40 ± 2 °C with 75 ± 5% RH during a 6-month period while critical properties remained stable. The cytotoxicity analysis showed significant concentration-dependent toxicity effects over a 48-h period leading to 29.85% cell viability at a 75 µg/mL concentration level while exhibiting similar toxicity as standard 5-FU treatment. The LCYS-LFF-MSNs demonstrated optimized physicochemical properties, remarkable stability, and promising in vitro anticancer activity, representing a novel zwitterionic nanocarrier system for Lappaol F delivery.